Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression

Med Hypotheses. 2007;68(1):235. doi: 10.1016/j.mehy.2006.06.027. Epub 2006 Aug 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Breast / drug effects
  • Breast / metabolism*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Carcinoma, Ductal / drug therapy*
  • Carcinoma, Ductal / metabolism*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Humans
  • Injections, Intralesional
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / metabolism*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab